Key Metrics of Novartis AG
Revenue—FY 2020
Operating income$10.2B▲ 0.0% YoY
Net profit$8.1B▲ 0.0% YoY
Shareholders' equity$56.7B
Market cap$298BNVS · $156.08
Competitors10identified
About Novartis AG
Sectors
Company details
- Listed
- NYSE: NVS
Operational Areas of Novartis AG
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameNovartis AG
TickerNVS
ExchangeNYSE
CountrySwitzerland
SEC CIK0001114448
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
NVS · NYSE · SEC CIK 0001114448
Last price · 29 Oct 2026
$156.08
−0.50%
Market cap$298B
P/E44.3On FY 2020 diluted EPS
Volume1,945,357
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOSwitzerland
NVS share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Novartis AG
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States |
Similar companies
A
Alector Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
P
Palisade Bio Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
E
Entera Bio Ltd.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
W
Wave Life Sciences Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
A
Ardelyx Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
CeriBell Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
N
Nuvation Bio Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
S
Septerna Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.